Nateglinide
![]() | |
Clinical data | |
---|---|
Trade names | Starlix |
AHFS/Drugs.com | Monograph |
MedlinePlus | a699057 |
License data |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 98% |
Elimination half-life | 1.5 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.170.086 ![]() |
Chemical and physical data | |
Formula | C19H27NO3 |
Molar mass | 317.429 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
![]() ![]() |
Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by Ajinomoto, a Japanese company and sold by the Swiss pharmaceutical company Novartis.
Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.
Pharmacology[]
Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells. This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.
Contraindications[]
Nateglinide is contraindicated in patients who:
- have known hypersensitivity to the compound or any ingredient in the formulation.
- are affected with type 1 (namely insulin-dependent) diabetes mellitus.
- are in diabetic ketoacidosis.
Comparisons with other drugs for type 2 diabetes[]
A study funded by Novo Nordisk, the U.S. distributor for Repaglinide, compared their product with Nateglinide in "A randomized, parallel-group, open-label, multicenter 16-week clinical trial".[1] They concluded that the two were similar, but "repaglinide monotherapy was significantly more effective than nateglinide monotherapy in reducing HbA1c and FPG values after 16 weeks of therapy."
Dosage[]
Nateglinide is delivered in 60 mg & 120 mg tablet form.
See also[]
- Repaglinide
References[]
- ^ Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM (June 2004). "Repaglinide versus nateglinide monotherapy: a randomized, multicenter study". Diabetes Care. American Diabetes Association. 27 (6): 1265–70. doi:10.2337/diacare.27.6.1265. PMID 15161773. Retrieved 2014-11-20.
External links[]
- Starlix - website of the manufacturer.
- How Nateglinide Works - website of the manufacturer.
- Potassium channel blockers
- Meglitinides
- Carboxamides
- Isopropyl compounds
- Cyclohexanes